key: cord-0950326-7xxuwyua
authors: Dillman, Alison; Park, Jay J.H.; Zoratti, Michael J.; Zannat, Noor-E; Lee, Zelyn; Dron, Louis; Hsu, Grace; Smith, Gerald; Khakabimamaghani, Sahand; Harari, Ofir; Thorlund, Kristian; Mills, Edward J.
title: Reporting and design of randomized controlled trials for COVID-19: A systematic review
date: 2020-12-03
journal: Contemp Clin Trials
DOI: 10.1016/j.cct.2020.106239
sha: 165c36e14ce0e112c5e3726d268380aa96db9adf
doc_id: 950326
cord_uid: 7xxuwyua

BACKGROUND: The novel coronavirus 2019 (COVID-19) pandemic has mobilized global research at an unprecedented scale. While challenges associated with the COVID-19 trial landscape have been discussed previously, no comprehensive reviews have been conducted to assess the reporting, design, and data sharing practices of randomized controlled trials (RCTs). PURPOSE: The purpose of this review was to gain insight into the current landscape of reporting, methodological design, and data sharing practices for COVID-19 RCTs. DATA SOURCES: We conducted three searches to identify registered clinical trials, peer-reviewed publications, and pre-print publications. STUDY SELECTION: After screening eight major trial registries and 7844 records, we identified 178 registered trials and 38 publications describing 35 trials, including 25 peer-reviewed publications and 13 pre-prints. DATA EXTRACTION: Trial ID, registry, location, population, intervention, control, study design, recruitment target, actual recruitment, outcomes, data sharing statement, and time of data sharing were extracted. DATA SYNTHESIS: Of 178 registered trials, 112 (62.92%) were in hospital settings, median planned recruitment was 100 participants (IQR: 60, 168), and the majority (n = 166, 93.26%) did not report results in their respective registries. Of 35 published trials, 31 (88.57%) were in hospital settings, median actual recruitment was 86 participants (IQR: 55.5, 218), 10 (28.57%) did not reach recruitment targets, and 27 trials (77.14%) reported plans to share data. CONCLUSIONS: The findings of our study highlight limitations in the design and reporting practices of COVID-19 RCTs and provide guidance towards more efficient reporting of trial results, greater diversity in patient settings, and more robust data sharing.

The novel coronavirus 2019 (COVID-19) pandemic has mobilized global research at an unprecedented scale. Indeed, billions of dollars in funding have been invested in clinical trial research to facilitate the rapid evaluation of potential therapies and vaccines [1, 2] . By July 2020 over 1700 COVID-19 studies had been listed in international clinical trial registries [3] .

Despite the sheer volume of ongoing research, the fight against this pandemic has been largely inefficient [4] [5] [6] [7] . Few effective treatments have been identified [8] . The use of non-peer reviewed pre-print publishing has also rapidly expanded [9] . Yet, while challenges associated with trial feasibility in the context of the COVID-19 pandemic have been discussed previously [10] , no comprehensive evidence reviews have been conducted to assess the reporting, design, and data sharing practices of randomized controlled trials.

The purpose of this study was to evaluate the emerging randomized controlled trial (RCT) COVID-19 evidence with respect to the ability to rapidly disseminate findings, methodological designs, and data sharing practices of RCTs for COVID-19.

This systematic literature review was designed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines [11] .

Three information identification strategies were designed to identify registered clinical trials, peer-reviewed publications, and pre-print (i.e. non-peer reviewed) publications of RCTs of interventions for COVID- 19 .

To identify trials listed in clinical trial registries, we searched listings in: ClinicalTrials.gov; the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP); the European Clinical Trials Registry; the Chinese Clinical Trial Registry, the German Clinical Trials Register; the Japan Primary Registries Network, the Iranian Clinical Trial Registry, and the Australian New Zealand Clinical Trials Registry. Searches were conducted using the terms 'COVID-19 OR SARS-CoV-2 OR novel coronavirus 2019' or database-specific tools to list COVID-19 registered trials, where available, in all clinical trial registries up to 15 July 2020 [3] .

Second, we conducted systematic searches in MEDLINE and EMBASE (via Ovid) and the Cochrane Central Register of Controlled Trials (CENTRAL) to identify RCTs for the prevention or treatment of COVID-19 from 1 January 2020 to 12 July 2020 (Supplementary Tables 1-3) . Finally, a search was conducted on 15 July 2020 to identify pre-print publications on medRxiv and bioRxiv (Supplementary Table 4 ) [12] . These three strategies were supplemented by hand searches of the reference lists of full texts identified in the search.

Broad eligibility criteria were applied to select RCTs on the topic of prevention or treatment of patients with COVID-19 irrespective of interventions, controls, or outcomes ( Table 1) . The inclusion and exclusion criteria were applied to both the publications and registered trials (Table 1) . Given an anticipated delay from study completion to results dissemination, clinical trial registries with a primary completion date of 1 June 2020 or earlier were eligible for inclusion [13, 14] . Publications in languages other than English were excluded.

Two reviewers (AD and JJHP) independently reviewed all abstracts and proceedings identified in the literature searches. The full-text publications of potentially relevant abstracts were then retrieved and assessed for eligibility by two independent reviewers (AD and ZL). Trial registries were screened and reviewed by a paired group of six reviewers (NEZ, LD, GH, GS, SK, and OH). Hand searches were performed on the reference lists of full texts identified in the search (AD and ZL). Discrepancies in study selection were resolved by discussion or, when necessary, by a third investigator (KT or EJM).

Two independent reviewers (AD and ZL) extracted data into a standardized data extraction spreadsheet. For each eligible trial, we extracted the trial identifier, trial registry, study location sites, population of interest, intervention(s), control(s), study design, recruitment target, actual recruitment, and the outcomes to be collected. We also captured any plans to share data or formal data sharing statements, as well as the anticipated time of data sharing. Cross-checking for consistency was conducted by other reviewers (LD and KT). A risk of bias assessment was conducted by two reviewers (AD and ZL) according to the Cochrane Collaboration's risk-of-bias assessment tool [15] .

We summarized the characteristics of included trials and publications across three broad areas: 1) Completion versus reporting of registered clinical trials; 2) Methodological designs of published clinical trials; and 3) Data sharing agreements of published clinical trials.

Across the three data gathering strategies, we identified 178 trials in clinical trial registries, 7830 records in medical literature database, and 14 additional publications through hand searches of bibliographies and trial registries (Fig. 1 ). Of the 7844 abstracts, 319 records were selected for full-text review, with 38 publications (35 trials) satisfying all inclusion criteria. Twenty-five peer reviewed publications were identified, with an additional 13 pre-prints. A complete list of registered trials (Supplementary Table 5 ), included peer reviewed and preprint publications (Supplementary Tables 6 and 7) , excluded peer reviewed and preprint publications (Supplementary Table 8 ), and risk-of-bias assessments (Supplementary Table 9 ) are available in the supplemental materials.

Using the Cochrane risk of bias tool, the published RCTs were most often judged to have some concerns for randomization, deviations from intervention, measurement of the outcome, and selection of the reported results. The majority of trials were judged to have a low risk of missing outcome data. The overall risk of bias for most published trials was judged to have some concerns (Supplementary Table 9 ).

We identified 178 RCTs with a primary completion date of 1 June 2020 or earlier (Supplementary Table 10 ). Across these studies, the median planned enrollment was 100 participants (interquartile range [IQR]: 60, 186). Most trials (n = 112/178, 62.92%) were in hospital settings, compared to 25 trials (14.04%) in outpatient settings and four trials (2.25%) in prevention. Most trials were 2-arm studies (n = 139/ 178, 78.09%), while 26 (14.61%) were 3-arm studies, and 13 (7.30%) reported four or more arms. Trials were often open-label (n = 79/178, 44.38%), double blind (n = 28/178, 15.73%) or single blind (n = 12/ 178, 6.74%). Study sites most frequently included China (n = 90/178, 50.56%), Iran (n = 50/178, 28.09%), and the United States (n = 10/178, 5.62%). Seven (3.93%) of the 178 trials have indicated that they suspended their recruitment, 72 (40.45) reported they were recruiting, 43 (24.16%) were not recruiting, 2 (1.12%) reported an unclear status, while 54 trials (30.34%) indicated that they are complete. While twelve Peer-reviewed and non-peer-reviewed publications in the English language Registered randomized controlled trials with primary completion date on 1 June 2020 or earlier* * Trials were included with a primary date of completion by 1 June 2020 or earlier to provide reasonable time for preprints or publications with trial results. trials (6.74%) had linked publications to their respective trial registry entry, the vast majority of registry entries (n = 166/178, 93.26%) had not published any study results by 15 July 2020. While 35 trials have published their results, only twelve trials (n = 12/35, 34.29%) have linked a publication to a respective trial registry. Five of the published trials (n = 5/35, 14.29%) did not report clinical trial registration and 18 trials (n = 18/35, 51.43%) did not link publications in their respective registries. The vast majority of the 178 registered trials (n = 166/178, 93.25%) did not report study results in their respective registries by 15 July 2020.

Thirty-five RCTs were identified ( Table 2; Supplementary Tables 10  and 11 ), consisting of 24 peer-reviewed publications and 11 pre-prints. As observed in the registered trials with primary completion dates of 1 June 2020 or earlier, the majority of published trial evidence is from China (n = 22/35, 62.86%). Similarly, most trials were 2-arm designs (n = 30/35, 85.71%) and were in hospital settings (n = 31/35, 88.57%).

For the published trials, planned recruitment varied from 60 to 6000 participants with a median of 260 participants (IQR: 118.75, 443.25) while actual recruitment numbers varied from 21 to 6425 participants with a median of 86 participants (IQR: 55.5, 218). Ten clinical trials (n = 10/35, 28.57%) did not reach their recruitment target, with actual recruitment ranging from 18.4% to 94.0%, compared to 100.0% to 181.4% for the trials that did achieve their enrollment targets. However, the RECOVERY Trial, ACTT Trial, and ChiCTR2000029308 completed sample size reassessments during the trials and subsequently reached their recruitment target [16] [17] [18] . Of the ten clinical trials that did not reach recruitment targets, eight (n = 8/35, 22.86%) were due to feasibility constraints. The hydroxychloroquine inpatient clinical trial (NCT04342182) in Brazil was halted prematurely due to concerns about the potential benefit of the intervention [19] . Actual recruitment was limited in one trial due to ethical concerns which resulted in early stopping [19] .

As presented in Table 3 , most trials have reported plans to share data (n = 27/35, 77.14%). Of these, the mechanism of sharing is often upon individual request (n = 21/27, 77.78%). For instance, two trials conducted in China have reported that approval is required from the Human Genetic Resources Administration of China prior to data sharing [20, 21] . The stated time of data sharing varied from immediately upon trial completion to up to one year after publication.

To our knowledge, this is the first systematic review of registered clinical trials, peer-reviewed publications, and pre-print publications of COVID-19 RCTs that focuses specifically on reporting, methodological designs, and data sharing practices. While we accommodated for a time lag between study completion and results dissemination, the vast majority of the 178 registered trials had not yet published findings, either in peer-reviewed journals or in pre-print repositories. This finding highlights a need for more rapid and robust reporting practices, as effective dissemination is essential to reduce duplicated research efforts while providing much-needed guidance for future research, practice, and policy [22, 23] . Nearly all published trials were conducted with hospitalized patients, highlighting a lack of evidence emerging in the outpatient as well as pre-or post-exposure prophylaxis settings. While there is undoubtedly value in evaluating interventions for the most severely ill patients, there are several public health motivations to direct research efforts and funding to managing patients in the community or mitigating the risk of infection altogether. As most trials did not reach recruitment targets due to feasibility constraints, there are also concerns to be raised regarding the statistical underpowering of studies and the validity of findings from these investigations [24] [25] [26] [27] . However, this should be considered in light of trials or trial arms which were terminated early for ethical reasons and that the widespread limitations imposed by the pandemic may have impacted recruitment practices [19, 28] .

In most published trials, investigators indicated that data would be made available upon request, with timelines for such inquiries varying from immediately following publication to one year after findings were disseminated. While some trials have shared de-identified individual patient data, most trials have not yet made such data available [29] . Timely and robust data sharing is critical to ensuring that the efforts of both patients and investigators is sufficiently leveraged to yield potential health benefits, provide real-time guidance, and facilitate collaboration within the scientific community [22, 23] . Clinical trial protocols with robust and rapid data sharing are particularly warranted in this time of global health crisis. Our results highlight opportunities for enhanced data sharing across the scientific community. Such collaborations may advance our understanding of prevention and treatment of COVID-19, with rapid, real-world applications and meaningful implications for addressing the health, social, and economic burden of the virus [30] [31] [32] .

Our conclusions are based on a rigorous review of ongoing and completed trials in COVID-19, including systematic searches in international clinical registries, major medical literature databases, and preprint repositories. The inclusion of pre-print publications afforded a more complete picture of COVID-19 trial reporting practices, as this acknowledges the delays inherent to publishing through a peerreviewed process. As the evidence base for COVID-19 interventions continues to evolve, with new registered trials and completed trials reporting their findings, the conclusions drawn based on our review may change. However, we sought to provide a timely analysis of the early COVID-19 RCT research landscape to identify limitations and opportunities for individual researchers and the broader research community to improve reporting practices and enter into stronger, more effective collaborations.

This study has several limitations. First, not all RCTs are necessarily registered and our review of the 178 trials was limited to the most recently updated data available in the respective registries. Second, the phases of the trials varied and due to the small sample, there was likely high heterogeneity in the 35 published trials. Third, given the early nature of this study, the majority of published evidence was from China, thus the included trials are not representative of the conduct of trials globally. Fourth, our search strategy included hand searching to supplement our database searches and this introduces subjectivity. However, we sought to address this with two independent reviewers. Finally, we used a limited time interval to examine clinical trials from 1 January 2020 to 1 June 2020, thus the included trials are not representative of all active trials studying COVID-19. However, the purpose of this interval was to allow us to examine and report on the early clinical trial practices in response to COVID-19.

The findings of our study highlight the limitations of the reporting and feasibility of COVID-19 randomized controlled trials. This systematic review provides guidance for future trials, including a need for more efficient reporting of clinical trial results, greater diversity of clinical trial patient settings, and robust data sharing practices for meaningful and rapid real-world application to the COVID-19 pandemic.

No funding was received for this study.

AD, JJHP, and EJM conceptualized the study. AD, JJHP, MZ, NEZ, ZL, LD, GH, GS, SK, OH, KT, and EJM contributed to data curation; formal analysis; investigation; methodology; validation; visualization; and writing -review & editing. AD, JJHP, and MZ contributed to writing -original draft. JJHP, KT, and EJM provided project administration; resources; software; and supervision.

The authors do not have any competing interests.

World Health Organization declares global emergency: a review of the 2019 novel coronavirus (COVID-19)

Global health funding: how much, where it comes from and where it goes

A real-time dashboard of clinical trials for COVID-19

Editorial concern-possible reporting of the same patients with COVID-19 in different reports

Waste in covid-19 research

Editorial evaluation and peer review during a pandemic: how journals maintain standards

How swamped preprint servers are blocking bad coronavirus research

(2020) 1-11. Epub ahead of print

Early in the epidemic: impact of preprints on global discourse about COVID-19 transmissibility

COVID-19: a novel coronavirus and a novel challenge for critical care

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv, medRxiv

Pandemic publishing poses a new COVID-19 challenge

Randomized clinical trials and COVID-19: managing expectations

The cochrane collaboration's tool for assessing risk of bias in randomised trials

Effect of dexamethasone in hospitalized patients with COVID-19: preliminary report, medRxiv

Remdesivir for the treatment of Covid-19 -preliminary report

A trial of Lopinavir-ritonavir in adults hospitalized with severe Covid-19

Convalescent Plasma for COVID-19. A randomized clinical trial, medRxiv

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

High-flow nasal-oxygenation-assisted fibreoptic tracheal intubation in critically ill patients with COVID-19 pneumonia: a prospective randomised controlled trial

Sharing research data to improve public health

Data sharing and outbreaks: best practice exemplified

Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial

Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial

Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: Open label, randomised controlled trial

Efficacy and safety of lopinavir/ritonavir or arbidol in adult patients with mild/moderate COVID-19: an exploratory randomized controlled trial

Recruitment to randomised studies

A randomized trial of hydroxychloroquine as Postexposure prophylaxis for Covid-19

A global, neutral platform for sharing trial data

Covid-induced economic uncertainty

Covid-19-navigating the uncharted

Ramipril in high risk patients with COVID-19

Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial

A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19, Zhejiang Da Xue Xue Bao Yi Xue Ban

A randomized trial of instructor-led training versus video lesson in training health care providers in proper donning and doffing of personal protective equipment

Remdesivir for 5 or 10 days in patients with severe Covid-19

Efficacy and safety of Lianhuaqingwen capsules, a repurposed Chinese herb

Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial

Application of CareDose 4D combined with Karl 3D technology in the low dose computed tomography for the follow-up of COVID-19

Effects of progressive muscle relaxation on anxiety and sleep quality in patients with COVID-19

Respiratory rehabilitation in elderly patients with COVID-19: a randomized controlled study

Hydroxychloroquine for early treatment of adults with mild Covid-19: a randomized-controlled trial

Hydroxychloroquine in nonhospitalized adults with early COVID-19

Efficacy of internet-based integrated intervention on depression and anxiety symptoms in patients with COVID-19

Effect of Xuebijing injection on inflammatory markers and disease outcome of coronavirus disease 2019

Guideline-based Chinese herbal medicine treatment plus standard care for severe coronavirus disease 2019 (G-CHAMPS): evidence from China

Effect of colchicine vs standard care on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with coronavirus disease 2019: the GRECCO-19 randomized clinical trial

Pulmonary radiological change of COVID-19 patients with 99mTc-MDP treatment

Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial

Efficacy and safety of chloroquine or hydroxychloroquine in moderate type of COVID-19: a prospective open-label randomized controlled study

Favipiravir versus arbidol for COVID-19: a randomized clinical trial

A Randomized, single-blind, group sequential, active-controlled study to evaluate the clinical efficacy and safety of α-Lipoic acid for critically ill patients with coronavirus disease 2019(COVID-19)

A novel protein drug, novaferon, as the potential antiviral drug for COVID-19

Clinical outcomes and plasma concentrations of baloxavir marboxil and favipiravir in COVID-19 patients: an exploratory randomized

Efficacy and safety of interferon beta-1a in treatment of severe COVID-19: A randomized clinical trial, medRxiv (2020)

Supplementary data to this article can be found online at https://doi. org/10.1016/j.cct.2020.106239.